LEVODOPA + CARBIDOPA + ENTACAPON / 50/12.5/200mg; 75/18.75/200mg; 100/25/200mg; 150/37.5/200mg; 175/43.75/200mg; 200/50/200mg Tablet

Antiepileptic

NSAID

PDE5 Inhibitors - Erectile dysfunction

Selective serotonin reuptake inhibitors - Antidepressants

Nucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B

Nucleoside reverse transcriptase inhibitors (NRTI) - Hepatitis B

Anticholinergics & anti-floating agents (combi)- Functional gastrointestinal disorders

Antihistaminics & Leukotriene receptor antagonists (combi)- Rhinitis & Asthma

Selective beta blocking agents- Hypertension

Anticholinesterases - Dementia & Alzheimer

Leukotriene receptor antagonists - Rhinitis & Asthma

Stomatological preparations - local oral NSAID

Abdi İbrahim has been awarded the 'Equal Opportunity Model' (FEM) certificate, developed by KAGIDER with the technical support of the World Bank, to promote gender equality in business life and enhance women's productivity. Deniz Daver, President of Human and Culture Group, expressed their happiness in receiving this certificate, stating, “This certificate, which acknowledges companies' sensitive approaches to gender equality and women's empowerment in employment, is an important indicator reflecting Abdi İbrahim's vision of inclusiveness. We see FEM certificate as a reward for our determined and continuous efforts in this field.

Turkish pharmaceutical industry leader Abdi Ibrahim s journey began in 1912.In addition to its partnerships with more than 30 licensing firms across the globe, Abdi Ibrahim develops its own products with 250 brands and 500 products.Abdi Ibrahim has subsidiaries operating in 17 countries outside Turkey, exports to more than 70 countries from the European Union to Canada, North Africa to Asia and generates the highest employment rate in the Turkish pharmaceutical industry with 5500 qualified employees.